Key facts
- This page summarizes Stanley C. Erck's Form 4 filing for NOVAVAX INC (NVAX).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 16 Dec 2022, 16:00.
Stanley C. Erck - 14 Dec 2022 Form 4 Insider Report for NOVAVAX INC (NVAX)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- NVAX
- Reported as of
- 14 Dec 2022
- Net transaction value
- -$39,974
- SEC form
- 4
- Accepted by SEC
- 16 Dec 2022, 16:00:48 UTC
- Prior SEC filing
- 28 Sep 2022
- Next SEC filing
- 23 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ John A. Herrmann III, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Stanley C. Erck filed Form 4 for NOVAVAX INC (NVAX) on 16 Dec 2022.
Change
- Previous filing in this sequence was filed on 28 Sep 2022.
- Current net transaction value: -$39,974.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NVAX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +6,966
- Change %
- +22%
- Price
- Shares after
- 38,812
- Date
- 14 Dec 2022
- Ownership
- Direct
- Footnotes
- F1, F2
NVAX
transaction
Common Stock
Tax liability
- Transaction value
- $39,974
- Shares
- -2,320
- Change %
- -6%
- Price
- $17.23
- Shares after
- 36,492
- Date
- 14 Dec 2022
- Ownership
- Direct
- Footnotes
- F3, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NVAX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -6,966
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 6,967
- Date
- 14 Dec 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,966
- Exercise price
- Footnotes
- F2, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
The shares were received by the Reporting Person in connection with vesting of restricted stock units ("RSUs").
Footnote F2
Each RSU represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
Footnote F3
The shares were withheld by the Company to satisfy tax withholding obligations in connection with the vesting of RSUs.
Footnote F4
The shares reported on this Form 4 are subject to a lock-up agreement between the Reporting Person, J.P. Morgan Securities LLC and Jefferies LLC, dated December 14, 2022.
Footnote F5
The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment through such vesting date.